This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics (DFTX) unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results. Patients with generalized anxiety disorder, or GAD, showed a 5.4-point improvement compared with a placebo on the 56-point Hamilton Anxiety Rating Scale. That beat the 4-point improvement investors had been hoping to see, RBC Capital Markets analyst…